[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo, AstraZeneca
DS-8201: Data from P3 DESTINY-Breast02 trial (NCT03523585) for pre-treated HER2 breast cancer in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Data from P3 DESTINY-Breast03 trial (NCT03529110) for HER2-positive, unresectable and/or metastatic breast cancer in 2021 
P3 data
https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_clinical_trials_appendix.pdf
 
Oct 24, 2019
 
 
4157af46-e184-402c-bf7a-8f3384344162.jpg